Cardiovascular disease remains a leading global health burden, yet many preclinical systems still struggle to predict how candidate drugs will perform in the human heart.

People taking GLP-1 drugs had a 14% lower risk of experiencing a major heart event compared to those on a placebo. The benefits extended across the board: fewer deaths overall, fewer non-fatal heart ...

New research on tirzepatide, the drug behind Zepbound and Mounjaro, suggests it could significantly lower the risk of major cardiovascular event.

Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026.

Early treatment with the aldosterone antagonist eplerenone (Inspra, Pfizer) plus an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) slows the progression of ...

By Sneha S K May 5 (Reuters) - Cytokinetics said on Tuesday its experimental heart disease drug significantly improved symptoms of a genetic heart condition in a late-stage trial, sending its shares ...

Share on Pinterest A new study found that GLP1-RA medications may help lower the risk of a cardiovascular event in people with type 2 diabetes. Getty Images Researchers say GLP-1 drugs prescribed for ...

A trial by AIIMS shows digoxin may reduce worsening heart failure in rheumatic heart disease patients, offering a low-cost ...

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern Medicine's Center for Genetic Medicine, raised $300 million last month for its ...

Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and ...

A large-scale analysis suggests that GLP-1 receptor agonists may do more than manage weight or blood sugar. New research ...